Published in final edited form as:

Semin Dial. 2017 May ; 30(3): 232–234. doi:10.1111/sdi.12600.

Introduction to the Critical Balance – Residual Kidney Function and Incremental Transition to Dialysis

Yoshitsugu Obi, Jason Chou, and Kamyar Kalantar-Zadeh

Harold Simmons Center for Kidney Disease Research and Epidemiology, Division of Nephrology and Hypertension, University of California Irvine Medical Center, Orange, California

Obsession with dialysis adequacy is the prevailing dogma in the management of patients with end-stage renal disease (ESRD) and has overshadowed the needed attention to personalized dialysis treatment and preservation of residual kidney function (RKF). As dialysis therapy emerged in 1960's and early 1970's, a thrice-weekly hemodialysis schedule was laid down by the dialysis pioneers as the "standard of care" – one that would prevent uremic symptoms and offer "the best compromise" by permitting the treatment of many patients with limited resources.¹ The rapid (but now stalled) technological progress in hemodialysis therapy has been beneficial, but the many attempts to improve patient outcomes by increasing dialysis dose and frequency have failed to show definite clinical benefits. Recent reports from the Frequent Hemodialysis Network (FHN) Trial group have suggested mixed and even contradictory effects of frequent vs. thrice-weekly in-center hemodialysis on patient survival in that mortality was reduced in the FHN Daily Trial while increased in the FHN Nocturnal Trial.^{2,3}

What might account for such a difference in the effect of dialysis frequency within the same study group? The key may lie in the different characteristics of participants, in particular their RKF. The FHN Daily Trial included mainly long-term hemodialysis patients of whom two thirds were anuric,⁴ while the patients recruited for the FHN Nocturnal Trial were relatively new to dialysis with half having urine volumes of 500 ml/d or more.⁵ Hence, RKF may have obscured the benefit of dialysis dose or frequency,⁶ considering its pivotal role in maintaining fluid and metabolic homeostasis even at the low levels present in ESRD patients.⁷ Indeed, residual kidney clearance is more strongly associated with survival among both ESRD patients on hemodialysis and peritoneal dialysis than is dialytic urea clearance.^{8,9} Interestingly, the above mentioned FHN Nocturnal Trial showed faster RKF decline in the frequent hemodialysis group¹⁰ which may at least partly explain the unexpected higher mortality in this group.¹¹ Frequent hemodialysis also led to worse vascular access outcomes.¹²

Technological advances have made hemodialysis treatments more efficient, effective, and less costly, allowing for an expansion of the eligibility for dialysis treatment such that the percentage of patients with an estimated GFR of >10 mL/min/1.73m² at dialysis initiation in

the U.S. has increased from 13% in 1996 to 40% in 2013.¹³ The elderly population is also increasing, and almost a quarter of incidence ESRD patients were aged ≥ 75 years in 2013. Growing heterogeneity in this population clearly warrants individualized treatment, rather than the one-size-fits-all approach. “Personalized dialysis” may offer more favorable clinical outcomes, better quality of life, and yet more cost-savings.

To that end, an emerging strategy is incremental dialysis. While an incremental approach has commonly been employed among patients transitioning to peritoneal dialysis, the vast majority of maintenance hemodialysis patients in developed countries are initiated abruptly with thrice-weekly treatments irrespective of their RKF. This is despite the 2006 Kidney Disease Outcomes Quality Initiative (KDOQI) guidelines suggesting less frequent hemodialysis schedules among patients with “substantial” residual renal urea clearance (i.e., $K_{\text{ru}} \geq 3.0 \text{ mL/min/1.73m}^2$).¹⁴ This gap between guidelines and clinical practice may be attributed to the misconception that RKF would invariably decline rapidly and quickly become clinically irrelevant after hemodialysis initiation, a belief based on old and inconclusive data from early studies comparing changes in RKF between patients on hemodialysis vs. peritoneal dialysis.^{15–18} Some – but not all – studies suggest that the current use of biocompatible dialysis membranes have been associated with the slower rate of decline in RKF.^{19,20} Hemodialysis patients may, contrary to widespread belief, have similar rates of decline to patients on peritoneal dialysis if ultrapure dialysate or on-line hemodiafiltration is used.^{21–24}

Less frequent hemodialysis (including twice-weekly treatment) has been criticized and labeled as inferior or inadequate dialysis.²⁵ While we agree that dosing may be “inadequate” by conventional measures when infrequent hemodialysis is used in palliative dialysis strategies,^{26,27} that critique is unwarranted in other settings. Major knowledge gaps have persisted until very recently pertaining to the multitudes of advantages of an incremental approach to dialysis initiation and the criteria to identify those who would benefit the most from this and other less frequent hemodialysis regimens.

In this issue of *Seminars in Dialysis*, we have assembled a group of opinion leaders in dialysis to address several important and emerging topics related to the interplay between RKF and incremental dialysis. We commence our discussion with Ghahremani et al. providing us the first reported experience in any North American center in implementing incremental hemodialysis in a case-series of 13 new ESRD patients who incrementally transitioned to full dose dialysis therapy. They explore the criteria used to decide on implementing twice-weekly hemodialysis and the methodology for the incremental transition to more frequent dialysis at a major University of California program. We then join Kalantar-Zadeh et al. in discussing renal replacement therapy including the incremental hemodialysis approach in the large and growing United States Veterans population with advanced CKD. The report is worth noting when considering that dialysis therapy in Veterans Affairs medical centers has demonstrated better outcomes than other centers.

Yan et al. explore the China’s experience in incremental dialysis. They have gathered the studies and patient characteristics that are important in that they will help practitioners implement incremental dialysis treatment strategies. Then, Locatelli et al. bring us their

experience from Italy in discussing the role of nutrition and, specifically, a low protein diet in preserving RKF in incident ESRD patients transitioning to incremental dialysis as well as the key factors for successful implementation of this program in their patient population.

Chin et al. then bring us a practical approach to adequacy assessments for incremental dialysis that includes RKF. This approach allows us to provide customized individual patient care. Tangvoraphonkchai and Davenport then bring us the European perspective on incremental dialysis and its clinical benefits, considerations and current practice implementation. Lastly, Shafi et al. describe the lessons they learned in their studies on incremental dialysis and RKF by their application in home hemodialysis and personalized dialysis care.

We would like to thank our invited authors, who include some world's most renowned experts and opinion leaders in the field, for their important contributions to this novel and fast emerging area. We believe that the readers of this issue will gain much knowledge on the critical roles of RKF and potential impact of incremental dialysis on the health care system and patient quality of life. It is likely that with these and other contributions, incremental dialysis will become the standard of care in the coming years and that preservation of RKF will become a high priority goal that will be linked to quality of care incentives. We look forward to exciting future of personalized dialysis.

Acknowledgments

KKZ is supported by research grants from the NIH/NIDDK (K24 DK091419 and U01 DK102163) and philanthropic grants from Mr. Harold Simmons, Mr. Louis Chang, Dr. Joseph Lee and AVEO. YO is supported by the Uehara Memorial Foundation Research Fellowship.

References

1. Scribner BH, Cole JJ, Ahmad S, Blagg CR. Why thrice weekly dialysis? Hemodial Int. 2004; 8:188–192. [PubMed: 19379416]
2. Rocco MV, Daugirdas JT, Greene T, Lockridge RS, Chan C, Pierratos A, Lindsay R, Larive B, Chertow GM, Beck GJ, Eggers PW, Kliger AS. Long-term Effects of Frequent Nocturnal Hemodialysis on Mortality: The Frequent Hemodialysis Network (FHN) Nocturnal Trial. Am J Kidney Dis. 2015; 66:459–468. [PubMed: 25863828]
3. Chertow GM, Levin NW, Beck GJ, Daugirdas JT, Eggers PW, Kliger AS, Larive B, Rocco MV, Greene T. Frequent Hemodialysis Network Trials G. Long-Term Effects of Frequent In-Center Hemodialysis. J Am Soc Nephrol. 2016; 27:1830–1836. [PubMed: 26467779]
4. Chertow GM, Levin NW, Beck GJ, Daugirdas JT, Eggers PW, Kliger AS, Larive B, Rocco MV, Greene T. Long-Term Effects of Frequent In-Center Hemodialysis. J Am Soc Nephrol. 2015
5. Rocco MV, Lockridge RS Jr, Beck GJ, Eggers PW, Gassman JJ, Greene T, Larive B, Chan CT, Chertow GM, Copland M, Hoy CD, Lindsay RM, Levin NW, Ornt DB, Pierratos A, Pipkin MF, Rajagopalan S, Stokes JB, Unruh ML, Star RA, Kliger AS, Kliger A, Eggers P, Briggs J, Hostetter T, Narva A, Star R, Augustine B, Mohr P, Beck G, Fu Z, Gassman J, Daugirdas J, Hunsicker L, Li M, Mackrell J, Wiggins K, Sherer S, Weiss B, Sanz J, Dellagrottaglie S, Kariisa M, Tran T, West J, Unruh M, Keene R, Schlarb J, Chan C, McGrath-Chong M, Frome R, Higgins H, Ke S, Mandaci O, Owens C, Snell C, Eknayan G, Appel L, Cheung A, Derse A, Kramer C, Geller N, Grimm R, Henderson L, Prichard S, Roecker E, Rocco M, Miller B, Riley J, Schuessler R, Lockridge R, Pipkin M, Peterson C, Hoy C, Fensterer A, Steigerwald D, Stokes J, Somers D, Hilkin A, Lilli K, Wallace W, Franzwa B, Waterman E, Levin A, Sioson L, Cabezon E, Kwan S, Roger D, Lindsay R, Suri R, Champagne J, Bullas R, Garg A, Mazzorato A, Spanner E, Burkart J, Moossavi S, Mauck V, Kaufman T, Chan W, Regozo K, Kwok S. The effects of frequent nocturnal home hemodialysis: the

- Frequent Hemodialysis Network Nocturnal Trial. *Kidney Int.* 2011; 80:1080–1091. [PubMed: 21775973]
6. Obi Y, Eriguchi R, Ou SM, Rhee CM, Kalantar-Zadeh K. What Is Known and Unknown About Twice-Weekly Hemodialysis. *Blood Purif.* 2015; 40:298–305. [PubMed: 26656764]
 7. Mathew AT, Fishbane S, Obi Y, Kalantar-Zadeh K. Preservation of residual kidney function in hemodialysis patients: reviving an old concept. *Kidney Int.* 2016; 90:262–271. [PubMed: 27182000]
 8. Bargman JM, Thorpe KE, Churchill DN. Relative contribution of residual renal function and peritoneal clearance to adequacy of dialysis: a reanalysis of the CANUSA study. *J Am Soc Nephrol.* 2001; 12:2158–2162. [PubMed: 11562415]
 9. Termorshuizen F, Dekker FW, van Manen JG, Korevaar JC, Boeschoten EW, Krediet RT. Relative contribution of residual renal function and different measures of adequacy to survival in hemodialysis patients: an analysis of the Netherlands Cooperative Study on the Adequacy of Dialysis (NECOSAD)-2. *J Am Soc Nephrol.* 2004; 15:1061–1070. [PubMed: 15034110]
 10. Daugirdas JT, Greene T, Rocco MV, Kaysen GA, Depner TA, Levin NW, Chertow GM, Ornt DB, Raimann JG, Larive B, Klinger AS. Effect of frequent hemodialysis on residual kidney function. *Kidney Int.* 2013; 83:949–958. [PubMed: 23344474]
 11. Obi Y, Rhee CM, Mathew AT, Shah G, Streja E, Brunelli SM, Kovesdy CP, Mehrotra R, Kalantar-Zadeh K. Residual Kidney Function Decline and Mortality in Incident Hemodialysis Patients. *J Am Soc Nephrol.* 2016; 27:3758–3768. [PubMed: 27169576]
 12. Suri RS, Larive B, Sherer S, Eggers P, Gassman J, James SH, Lindsay RM, Lockridge RS, Ornt DB, Rocco MV, Ting GO, Klinger AS. Risk of vascular access complications with frequent hemodialysis. *J Am Soc Nephrol.* 2013; 24:498–505. [PubMed: 23393319]
 13. U.S. Renal Data System. USRDS 2015 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; Bethesda, MD: 2015.
 14. National Kidney Foundation. KDOQI Clinical Practice Guidelines for Hemodialysis Adequacy, Update 2006. *Am J Kidney Dis.* 2006; 48(Suppl 1):S2–90. [PubMed: 16813990]
 15. Lysaght MJ, Vonesh EF, Gotch F, Ibels L, Keen M, Lindholm B, Nolph KD, Pollock CA, Prowant B, Farrell PC. The influence of dialysis treatment modality on the decline of remaining renal function. *ASAIO Trans.* 1991; 37:598–604. [PubMed: 1768496]
 16. Moist LM, Port FK, Orzol SM, Young EW, Ostbye T, Wolfe RA, Hulbert-Shearon T, Jones CA, Bloembergen WE. Predictors of loss of residual renal function among new dialysis patients. *J Am Soc Nephrol.* 2000; 11:556–564. [PubMed: 10703680]
 17. Misra M, Vonesh E, Van Stone JC, Moore HL, Prowant B, Nolph KD. Effect of cause and time of dropout on the residual GFR: a comparative analysis of the decline of GFR on dialysis. *Kidney Int.* 2001; 59:754–763. [PubMed: 11168959]
 18. Jansen MA, Hart AA, Korevaar JC, Dekker FW, Boeschoten EW, Krediet RT. Predictors of the rate of decline of residual renal function in incident dialysis patients. *Kidney Int.* 2002; 62:1046–1053. [PubMed: 12164889]
 19. Van Stone JC. The effect of dialyzer membrane and etiology of kidney disease on the preservation of residual renal function in chronic hemodialysis patients. *ASAIO J.* 1995; 41:M713–716. [PubMed: 8573899]
 20. Hartmann J, Fricke H, Schiff H. Biocompatible membranes preserve residual renal function in patients undergoing regular hemodialysis. *Am J Kidney Dis.* 1997; 30:366–373. [PubMed: 9292565]
 21. Schiff H, Lang SM, Fischer R. Ultrapure dialysis fluid slows loss of residual renal function in new dialysis patients. *Nephrol Dial Transplant.* 2002; 17:1814–1818. [PubMed: 12270990]
 22. McKane W, Chandna SM, Tattersall JE, Greenwood RN, Farrington K. Identical decline of residual renal function in high-flux biocompatible hemodialysis and CAPD. *Kidney Int.* 2002; 61:256–265. [PubMed: 11786108]
 23. Penne EL, van der Weerd NC, van den Dorpel MA, Grooteman MP, Levesque R, Nube MJ, Bots ML, Blankestijn PJ, ter Wee PM. Short-term effects of online hemodiafiltration on phosphate control: a result from the randomized controlled Convective Transport Study (CONTRAST). *Am J Kidney Dis.* 2010; 55:77–87. [PubMed: 19962805]

24. Schiff H, Lang SM, Fischer R. Effects of high efficiency post-dilution on-line hemodiafiltration or conventional hemodialysis on residual renal function and left ventricular hypertrophy. *Int Urol Nephrol*. 2013; 45:1389–1396. [PubMed: 23225079]
25. Vanholder R, Van Biesen W, Lameire N. Is starting hemodialysis on a twice-weekly regimen a valid option? *Am J Kidney Dis*. 2014; 64:165–167. [PubMed: 25060001]
26. Rhee CM, Unruh M, Chen J, Kovesdy CP, Zager P, Kalantar-Zadeh K. Infrequent dialysis: a new paradigm for hemodialysis initiation. *Semin Dial*. 2013; 26:720–727. [PubMed: 24016197]
27. Rhee CM, Ghahremani-Ghajar M, Obi Y, Kalantar-Zadeh K. Incremental and infrequent hemodialysis: a new paradigm for both dialysis initiation and conservative management. *Panminerva Med*. 2017 in press.